Volume 58, Issue 3 pp. 308-312
Research Report

Treatment of suture line bleeding with a novel synthetic surgical sealant in a canine iliac PTFE graft model

Arthur Hill

Arthur Hill

Department of Cardiothoracic Surgery, University of California, San Francisco, California

Search for more papers by this author
Trudy D. Estridge

Corresponding Author

Trudy D. Estridge

Cohesion Technologies, Inc., 2500 Faber Place, Palo Alto, California

Cohesion Technologies, 2500 Faber Place, Palo Alto, CA 94303Search for more papers by this author
Marcee Maroney

Marcee Maroney

Cohesion Technologies, Inc., 2500 Faber Place, Palo Alto, California

Search for more papers by this author
Eric Monnet

Eric Monnet

College of Veterinary Medicine, Colorado State University, Fort Collins, Colorado

Search for more papers by this author
Barbara Egbert

Barbara Egbert

Cohesion Technologies, Inc., 2500 Faber Place, Palo Alto, California

Search for more papers by this author
Greg Cruise

Greg Cruise

Cohesion Technologies, Inc., 2500 Faber Place, Palo Alto, California

Search for more papers by this author
George T. Coker

George T. Coker

Cohesion Technologies, Inc., 2500 Faber Place, Palo Alto, California

Search for more papers by this author

Abstract

CoSeal™ surgical sealant (CoSeal) was evaluated for inhibiting suture line bleeding using a canine iliac PTFE graft model. Both iliac arteries of 12 heparinized canines were grafted with PTFE. CoSeal was applied to the suture lines of one graft in each animal. The contra-lateral graft served as a control and bleeding was controlled with gauze and pressure (tamponade). The cross-clamps were removed 30 s following application of CoSeal. Times to hemostasis and volume of blood loss at each graft site were determined. Compared to tamponade control, CoSeal significantly reduced the time to hemostasis (average of 5 min vs. greater than 15 min, p < 0.05) and blood loss (19 g vs. 284 g, p < 0.05). Small amounts of CoSeal were visible grossly or histologically at day 7. Histology showed moderate to marked inflammation in CoSeal sites and moderate inflammation in control sites at day 7. At 30 and 60 days, no CoSeal was visible grossly or histologically. Histology showed moderate inflammation in both CoSeal treated sites and in control sites at day 30 and mild to moderate inflammation in both CoSeal and control sites at day 60. CoSeal significantly reduced the time to hemostasis and blood loss in comparison to tamponade. © 2001 John Wiley & Sons, Inc. J Biomed Mater Res (Appl Biomater) 58: 308–312, 2001

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.